Innovation centre for the translational analysis of multi-omics data linked to cerebrovascular disease.
Challenges and objectives
The advent of increasingly affordable high-throughput technologies (whole genome sequencing, multi-omics, etc.) is paving way to unprecedented prospects for biomedical research and personalised medicine and prevention.
The aim of the VBHI – Translational Omics Centre is to elucidate the molecular mechanisms of cerebrovascular disease, by combining expertise in genomics, metabolomics, proteomics and epigenomics. The power of multi-omics applied to studies following large numbers of people at all ages of adult life in the general population or patients with different conditions implicated in cerebrovascular disease enables unique approaches and new scientific frontiers.
Priority areas:
- To identify new molecular biomarkers for cerebral small vessel disease.
- To look at molecular signature to accelerate the identification of new therapeutic targets.
- To enable the development of personalised preventive and therapeutic approaches by classifying biological subtypes of disease.
In France, it is estimated that a 50% reduction in the avoidable risks associated with the impact of cerebrovascular disease could lead to savings of €4.2 billion a year (€3 billion for dementia and €1.2 billion for stroke).
Taking a personalised approach to the discovery of new drugs for the treatment of cerebral small vessel disease provides a path to achieve these objectives.
Our experts
Your help is essential in the fight against stroke and dementia, and for the promotion of healthy brain ageing.
By supporting cutting-edge research to develop new prevention strategies and personalised therapies for vascular brain diseases, you are helping reduce the burden of these diseases worldwide.
Your donation entitles you to a tax reduction.
E.g.: If I am taxable and I donate €50, my donation will only cost me €12 after tax reduction.